Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 421 - 439 ( 439 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:14 EPS, ProHema IND Amended for Pediatric Patients, PROMPT Study to Start Mid-14, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4:13 Earnings, Pediatric Studies of ProHema in Blood Cancer and Rare Metabolic Diseases on Track, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in New Phase II Trial of ProHema, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in New Phase II Trial of ProHema, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Technology Found to Rapidly Produce Durable iPSCs, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Technology Found to Rapidly Produce Durable iPSCs, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Improved Safety with ProHema, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Improved Safety with ProHema, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3:13 EPS: New Formulation Ready for the Clinic in H1:14, Two Wnt7a Leads Picked for IND-Enabling Studies, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage With an OUTPERFORM Rating and $14 Price Target; Fated to Create Better Stem Cells
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 75.00